Liquid-Phase Plasma for Obesity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current obesity treatment methods, including pharmaceuticals and surgical interventions, have limitations such as side effects and inadequate persistence of efficacy, highlighting the need for a new approach that targets the inhibition of adipogenic differentiation to effectively manage obesity.
Innovation Solution
A composition utilizing liquid type plasma, produced by exposing a liquid material to non-thermal atmospheric-pressure plasma, which inhibits adipogenic differentiation and reduces intracellular lipogenesis, is developed for preventing and treating obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional obesity treatment methods (pharmaceuticals and surgical interventions) are used, then weight loss can be achieved, but side effects and inadequate persistence of efficacy occur
Solution Approach 1:
The patent uses liquid type plasma as an intermediary substance that mediates the treatment effect. Instead of directly applying pharmaceuticals or surgical interventions that cause side effects, the plasma serves as a carrier containing bioactive factors that inhibit adipogenic differentiation. This intermediary approach achieves weight loss while avoiding the harmful side effects of conventional treatments.
Solution Approach 2:
The patent replaces mechanical surgical interventions with a biochemical approach using liquid type plasma. Rather than physically removing or restricting adipose tissue through surgery, the treatment uses plasma-derived bioactive factors to regulate adipocyte differentiation at the molecular level, substituting mechanical intervention with a gentler biochemical mechanism.
2Reliability
If direct plasma treatment is applied, then adipogenic differentiation can be inhibited, but treatment efficacy is insufficient
Solution Approach 1:
The patent extracts the beneficial bioactive factors from plasma and concentrates them in liquid type plasma. By separating and concentrating the active components (such as growth factors, cytokines, and other bioactive molecules) from the plasma matrix, the treatment achieves higher efficacy in inhibiting adipogenic differentiation compared to using whole plasma or direct plasma treatment.
Solution Approach 2:
The patent changes the physical and chemical parameters of plasma to create liquid type plasma with enhanced therapeutic properties. By controlling plasma generation conditions and liquidification parameters, the treatment optimizes the concentration and activity of bioactive factors, thereby improving inhibition effectiveness against adipogenic differentiation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liquid type plasma composition significantly inhibits adipogenic differentiation and reduces intracellular lipogenesis, offering superior efficacy compared to direct plasma treatment, making it a promising approach for obesity prevention and treatment.
Implementation Method 1
liquid type plasma, produced by exposing a liquid material to non-thermal atmospheric-pressure plasma
Data Source
AI summary
Provided is a composition for obesity treatment comprising a liquid-phase plasma. More particularly, provided is a method for producing a liquid-phase plasma for inhibiting adipocyte differentiation or proliferation, a pharmaceutical composition for obesity prevention or treatment using a liquid-phase plasma produced according to the method, and a method for obesity prevention or treatment using the liquid-phase plasma.